Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 13/20 | 0.63 |
| ▸ | CRBN | Q96SW2 | 13/20 | 0.63 |
| ▸ | STAT3 | P40763 | 3/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | IL1B | P01584 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.53 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25731159 | 0.91 | DDB1 (0.65) | DDB1CRBNSTAT3IKZF3TNF | |
| SCHEMBL25878614 | 0.91 | CRBN (0.58) | DDB1CRBNSTAT3IKZF3TNF | |
| SCHEMBL24621138 | 0.89 | CRBN (0.64) | DDB1CRBNSTAT3MAP1LC3BHDAC1 | |
| SCHEMBL25878607 | 0.89 | CRBN (0.60) | DDB1CRBNSTAT3IKZF3TNF | |
| SCHEMBL23568580 | 0.88 | CRBN (0.68) | DDB1CRBNSTAT3IKZF3TNF | |
| SCHEMBL21997001 | 0.87 | CRBN (0.67) | DDB1CRBNSTAT3IKZF3TNF | |
| SCHEMBL24621495 | 0.87 | CRBN (0.71) | DDB1CRBNSTAT3MAP1LC3B | |
| SCHEMBL23568155 | 0.86 | DDB1 (0.64) | DDB1CRBNSTAT3IKZF3TNF | |
| SCHEMBL23672431 | 0.86 | DDB1 (0.64) | DDB1CRBNSTAT3IKZF3TNF | |
| SCHEMBL23696180 | 0.86 | DDB1 (0.64) | DDB1CRBNSTAT3IKZF3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885STAT3 145/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885STAT3 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.